Health minister Greg Hunt has confirmed flu vaccines from GSK, Sanofi and Seqirus will be funded through the National Immunisation Program (NIP) in 2017.
The 2017 quadrivalent influenza vaccines will cover two A strains of influenza (Michigan and Hong Kong) and two B strains of influenza (Brisbane and Phuket), as recommended by the World Health Organization.
Around 4.5 million doses of flu vaccine will be made available through the NIP in 2017.
GSK's FLUARIX TETRA will be supplied for eligible people aged three years and older.
Sanofi's FLUQUADRI will also be supplied for eligible people aged three years and older. The company's FLUQUADRI JUNIOR will be supplied for eligible children aged six months to less than three years.
Seqirus will supply AFLURIA QUAD will be supplied for people aged 18 years and older.
Influenza is estimated to be responsible for more than 5,000 hospitalisations and almost 170 deaths in Australia each year.